bunazosin has been researched along with Obesity in 5 studies
bunazosin: structure
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated the effect of a slow-release alpha1-receptor blocker, bunazosin hydrochloride, on leptin levels and insulin resistance in obese hypertensive patients with hyperleptinemia." | 9.12 | An alpha1-receptor blocker reduces plasma leptin levels in hypertensive patients with obesity and hyperleptinemia. ( Ihara, S; Kawana, M; Sakai, R; Shimamoto, K; Watanabe, H, 2006) |
| "To investigate insulin insensitivity and its reversibility, we performed an insulin sensitivity test using the steady state plasma glucose (SSPG) method in 10 lean hypertensive subjects with normal glucose tolerance before and after treatment with alpha 1-blocker bunazosin, and 14 age body mass index-adjusted healthy control subjects." | 7.68 | Insulin insensitivity in nonobese, nondiabetic essential hypertension and its improvement by an alpha 1-blocker (bunazosin). ( Asakura, Y; Harano, Y; Hirose, J; Kageyama, A; Omae, T; Sato, A; Suzuki, M, 1992) |
| " We investigated the effect of a slow-release alpha1-receptor blocker, bunazosin hydrochloride, on leptin levels and insulin resistance in obese hypertensive patients with hyperleptinemia." | 5.12 | An alpha1-receptor blocker reduces plasma leptin levels in hypertensive patients with obesity and hyperleptinemia. ( Ihara, S; Kawana, M; Sakai, R; Shimamoto, K; Watanabe, H, 2006) |
| "To investigate insulin insensitivity and its reversibility, we performed an insulin sensitivity test using the steady state plasma glucose (SSPG) method in 10 lean hypertensive subjects with normal glucose tolerance before and after treatment with alpha 1-blocker bunazosin, and 14 age body mass index-adjusted healthy control subjects." | 3.68 | Insulin insensitivity in nonobese, nondiabetic essential hypertension and its improvement by an alpha 1-blocker (bunazosin). ( Asakura, Y; Harano, Y; Hirose, J; Kageyama, A; Omae, T; Sato, A; Suzuki, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ihara, S | 1 |
| Shimamoto, K | 1 |
| Watanabe, H | 1 |
| Sakai, R | 1 |
| Kawana, M | 1 |
| Bönner, G | 1 |
| Schmieder, R | 1 |
| Chrosch, R | 1 |
| Weidinger, G | 1 |
| Weichenhain, B | 1 |
| Stemplinger, J | 1 |
| Ziegler, AG | 1 |
| Rabl, W | 1 |
| Standl, E | 1 |
| Stiegler, H | 1 |
| Suzuki, M | 1 |
| Hirose, J | 1 |
| Asakura, Y | 1 |
| Sato, A | 1 |
| Kageyama, A | 1 |
| Harano, Y | 1 |
| Omae, T | 1 |
| Kobatake, T | 1 |
| Watanabe, Y | 1 |
| Matsuzawa, Y | 1 |
| Tokunaga, K | 1 |
| Fujioka, S | 1 |
| Kawamoto, T | 1 |
| Keno, Y | 1 |
| Tarui, S | 1 |
| Yoshida, H | 1 |
2 trials available for bunazosin and Obesity
| Article | Year |
|---|---|
An alpha1-receptor blocker reduces plasma leptin levels in hypertensive patients with obesity and hyperleptinemia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; | 2006 |
Effect of bunazosin and atenolol on glucose metabolism in obese, nondiabetic patients with primary hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood | 1997 |
3 other studies available for bunazosin and Obesity
| Article | Year |
|---|---|
[Alström syndrome--a rare disease of diabetic association].
Topics: Adult; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diagnosis, Differential; DNA Mutational Analysi | 1997 |
Insulin insensitivity in nonobese, nondiabetic essential hypertension and its improvement by an alpha 1-blocker (bunazosin).
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Apoproteins; Blood Glucose; Blood Pressure; Catecholamine | 1992 |
Age-related changes in adrenergic alpha 1, alpha 2, and beta receptors of rat white fat cell membranes: an analysis using [3H]bunazosin as a novel ligand for the alpha 1 adrenoceptor.
Topics: Adipose Tissue; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aging; Animals; Binding S | 1991 |